These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 25742225)

  • 1. The role of routine clinical pretreatment 18F-FDG PET/CT in predicting outcome of colorectal liver metastasis.
    Tam HH; Cook GJ; Chau I; Drake B; Zerizer I; Du Y; Cunningham D; Koh DM; Chua SS
    Clin Nucl Med; 2015 May; 40(5):e259-64. PubMed ID: 25742225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
    Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ
    Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Standardized added metabolic activity (SAM) IN ¹⁸F-FDG PET assessment of treatment response in colorectal liver metastases.
    Mertens J; De Bruyne S; Van Damme N; Smeets P; Ceelen W; Troisi R; Laurent S; Geboes K; Peeters M; Goethals I; Van de Wiele C
    Eur J Nucl Med Mol Imaging; 2013 Aug; 40(8):1214-22. PubMed ID: 23636802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does a novel penalized likelihood reconstruction of 18F-FDG PET-CT improve signal-to-background in colorectal liver metastases?
    Parvizi N; Franklin JM; McGowan DR; Teoh EJ; Bradley KM; Gleeson FV
    Eur J Radiol; 2015 Oct; 84(10):1873-8. PubMed ID: 26163992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic value of
    Grut H; Dueland S; Line PD; Revheim ME
    Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):218-225. PubMed ID: 29026950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective evaluation of 18F-fluorodeoxyglucose positron emission tomography in patients receiving hepatic arterial and systemic chemotherapy for unresectable colorectal liver metastases.
    Correa-Gallego C; Gavane S; Grewal R; Cercek A; Klimstra DS; Gewirtz AN; Kingham TP; Fong Y; DeMatteo RP; Allen PJ; Jarnagin WR; Kemeny N; D'Angelica MI
    HPB (Oxford); 2015 Jul; 17(7):644-50. PubMed ID: 26010778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of early ¹⁸F-FDG PET/CT in prediction of progression-free survival after ⁹⁰Y radioembolization: comparison with RECIST and tumour density criteria.
    Zerizer I; Al-Nahhas A; Towey D; Tait P; Ariff B; Wasan H; Hatice G; Habib N; Barwick T
    Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1391-9. PubMed ID: 22644713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F-FDG PET/CT in salivary gland carcinomas.
    Ryu IS; Kim JS; Roh JL; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    J Nucl Med; 2013 Jul; 54(7):1032-8. PubMed ID: 23670902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reproducibility of functional volume and activity concentration in 18F-FDG PET/CT of liver metastases in colorectal cancer.
    Heijmen L; de Geus-Oei LF; de Wilt JH; Visvikis D; Hatt M; Visser EP; Bussink J; Punt CJ; Oyen WJ; van Laarhoven HW
    Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1858-67. PubMed ID: 22945372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic tumor volume and total lesion glycolysis on FDG-PET/CT can predict overall survival after (90)Y radioembolization of colorectal liver metastases: A comparison with SUVmax, SUVpeak, and RECIST 1.0.
    Shady W; Kishore S; Gavane S; Do RK; Osborne JR; Ulaner GA; Gonen M; Ziv E; Boas FE; Sofocleous CT
    Eur J Radiol; 2016 Jun; 85(6):1224-31. PubMed ID: 27161074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic modeling for patients with colorectal liver metastases incorporating FDG PET radiomic features.
    Rahmim A; Bak-Fredslund KP; Ashrafinia S; Lu L; Schmidtlein CR; Subramaniam RM; Morsing A; Keiding S; Horsager J; Munk OL
    Eur J Radiol; 2019 Apr; 113():101-109. PubMed ID: 30927933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
    Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early PET/CT scan is more effective than RECIST in predicting outcome of patients with liver metastases from colorectal cancer treated with preoperative chemotherapy plus bevacizumab.
    Lastoria S; Piccirillo MC; Caracò C; Nasti G; Aloj L; Arrichiello C; de Lutio di Castelguidone E; Tatangelo F; Ottaiano A; Iaffaioli RV; Izzo F; Romano G; Giordano P; Signoriello S; Gallo C; Perrone F
    J Nucl Med; 2013 Dec; 54(12):2062-9. PubMed ID: 24136935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretreatment quantitative
    Gencturk M; Ozturk K; Koksel Y; Li F; Cayci Z
    Clin Imaging; 2019; 53():17-24. PubMed ID: 30308429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of volume-based FDG PET/CT parameters in patients with locally advanced pancreatic cancer treated with chemoradiation therapy.
    Choi HJ; Lee JW; Kang B; Song SY; Lee JD; Lee JH
    Yonsei Med J; 2014 Nov; 55(6):1498-506. PubMed ID: 25323885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer.
    Fendler WP; Philippe Tiega DB; Ilhan H; Paprottka PM; Heinemann V; Jakobs TF; Bartenstein P; Hacker M; Haug AR
    J Nucl Med; 2013 Aug; 54(8):1202-8. PubMed ID: 23729697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Value of Total Lesion Glycolysis Measured by 18F-FDG-PET/CT in Patients with Colorectal Cancer.
    Ogawa S; Itabashi M; Kondo C; Momose M; Sakai S; Kameoka S
    Anticancer Res; 2015 Jun; 35(6):3495-500. PubMed ID: 26026116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of standardized uptake value and metabolic tumour volume on ¹⁸F-FDG PET/CT in oropharyngeal squamous cell carcinoma.
    Kim JW; Oh JS; Roh JL; Kim JS; Choi SH; Nam SY; Kim SY
    Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1353-61. PubMed ID: 26067088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of metabolic parameters in patients with synchronous colorectal cancer liver metastasis following curative-intent colorectal and hepatic surgery.
    Lee HS; Kim HO; Hong YS; Kim TW; Kim JC; Yu CS; Kim JS
    J Nucl Med; 2014 Apr; 55(4):582-9. PubMed ID: 24549284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early post-treatment FDG PET predicts survival after 90Y microsphere radioembolization in liver-dominant metastatic colorectal cancer.
    Sabet A; Meyer C; Aouf A; Sabet A; Ghamari S; Pieper CC; Mayer K; Biersack HJ; Ezziddin S
    Eur J Nucl Med Mol Imaging; 2015 Mar; 42(3):370-6. PubMed ID: 25351506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.